Material Transfer and License Option Agreement between Helix BioPharma Corporation and Schering CorporationMaterial Transfer and License Option Agreement • February 5th, 2009 • Helix BioPharma Corp • Pharmaceutical preparations • New York
INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS IDENTIFIED BY THREE ASTERISKS, AS FOLLOWS “* * *”, AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
MIGENIX and Schering-Plough Sign Agreement for MX-3253 Hepatitis C Drug Development and License OptionMaterial Transfer and License Option Agreement • July 13th, 2005 • MIGENIX Inc. • Pharmaceutical preparations
Vancouver, BC, CANADA & San Diego, CA, USA – July 13, 2005– MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has completed a Material Transfer and License Option Agreement (“Agreement”) with Schering-Plough Corporation (NYSE: SGP) of Kenilworth, N.J., related to celgosivir (MX-3253), MIGENIX’s first-in-class compound in Phase II clinical development for the treatment of chronic Hepatitis C Virus (HCV) infections.
MATERIAL TRANSFER AND LICENSE OPTION AGREEMENTMaterial Transfer and License Option Agreement • January 18th, 2007 • MIGENIX Inc. • Pharmaceutical preparations • New Jersey
THIS MATERIAL TRANSFER AGREEMENT (the “Agreement”) is made as of July 13th, 2005 (the “Effective Date”), by and between Migenix Inc., a corporation having its principal offices at 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2 Canada (“Migenix”), and Schering Corporation, a New Jersey corporation, having offices at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (“Schering”).
MATERIAL TRANSFER AND LICENSE OPTION AGREEMENTMaterial Transfer and License Option Agreement • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations • New Jersey
This Material Transfer Agreement (the “Agreement”) is made as of July 13th, 2005 (the “Effective Date”), by and between Migenix Inc., a corporation having its principal offices at 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2 Canada (“Migenix”), and Schering Corporation, a New Jersey corporation, having offices at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (“Schering”).
